Is epithelioid hemangioendothelioma curable?
Although localized epithelioid hemangioendothelioma can be surgically resected, there is no effective therapy for systemic disease, and mortality from the cancer ranges between 13% and 18% when confined to soft tissue, but life expectancy in metastatic cases is unpredictable and ranges from a couple of months to 15 to …
Is epithelioid hemangioendothelioma malignant?
Background. Epithelioid hemangioendothelioma (EHE) is a rare malignant vascular neoplasm with increasing incidence. However, its clinical characteristics remain unclear due to its low incidence.
What is hemangioendothelioma?
The term hemangioendothelioma describes several types of vascular neosplasms and includes both non-cancerous (benign) and cancerous (malignant) growths. The term has also been applied to those that show “borderline” behavior, intermediate between entirely benign hemangiomas and highly malignant angiosarcomas.
What is Pseudomyogenic hemangioendothelioma?
Pseudomyogenic hemangioendothelioma (PMHE) is a rare vascular tumor that was added to the World Health Organization classification of soft tissue tumors. These tumors have a unique clinical presentation and microscopic appearance as compared to other vascular tumors in the differential diagnosis.
What is metastatic epithelioid hemangioendothelioma?
Epithelioid hemangioendothelioma, or EHE, is a rare cancer that grows from the cells that make up the blood vessels. This cancer can occur anywhere in the body with the most common sites being the liver, lungs, and bone.
What is hepatic epithelioid hemangioendothelioma?
Hepatic epithelioid hemangioendothelioma (EHE) is a very rare malignant vascular tumor composed of epithelioid and histiocytoid endothelial cells in a myxohyaline or fibrous stroma. It may also occur in the lungs, soft tissue and bone.
Who Pseudomyogenic Hemangioendothelioma?
Pseudomyogenic hemangioendothelioma (PMHE) is a new entity. It is an intermediate soft tissue tumor clinically and/or histopathologically mimicking some other high-grade malignant tumors and some inflammatory diseases. We report a case of PMHE on the left plantar surface of a 28-year-old woman.
How many people have epithelioid hemangioendothelioma?
How common is epithelioid hemangioendothelioma? EHE is very rare, with only one in every one million people diagnosed with this cancer worldwide.
What is epithelioid angiomyolipoma?
Epithelioid angiomyolipoma is a rare tumor of mesenchymal tissue that has the potential for local invasion and disease progression. Diagnosis of EAML was confirmed by pathology and immunohistochemistry.
What is hepatic EHE?
What is the meaning of hepatoblastoma?
Hepatoblastoma is a rare tumor (an abnormal tissue growth) that originates in cells in the liver. It is the most common cancerous (malignant) liver tumor in early childhood.
How is epithelioid hemangioendothelioma ( EHE ) treated?
How is epithelioid hemangioendothelioma treated? Since EHE is so rare, there is no standard treatment. Treatment for each person is different and depends on where in the body EHE starts and if it has spread. You should see a doctor who is an expert in tumors that form in blood vessels to decide the best approach for your cancer.
What kind of tumor is pulmonary epithelioid hemangioendothelioma?
Introduction Pulmonary epithelioid hemangioendothelioma (PEH) was originally named intravascular bronchiolo-alveolar tumor (IVBAT) by Dail and Liebow in 1975 (1). PHE is a rare vascular tumor of low-grade malignancy and there is no clear standard for treatment. PEH typically occurs as bilateral multiple nodules among young females.
What kind of tumor is an epithelioid tumor?
Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor with an epithelioid and histiocytoid appearance, originating from vascular endothelial or pre-endothelial cells. It represents less than 1% of all vascular tumors and was described for the first time in 1975 by Dail and Liebow as pulmonary EHE (P-EHE).
What kind of chemotherapy is used for EHE?
Tyrosine kinase inhibitors: These drugs, designed as targeted therapies for cancers, have shown short-term success with EHE. Examples include sorafenib, sunitinib and pazopanib. Vincristine: This chemotherapy drug targets all dividing cells within the body and is therefore used to treat many cancers.